Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Forward chemical genetic screening is analogous to the classical genetics strategy of mutagenesis, except that a small molecule takes the place of a genetic mutation in altering the function of one or more gene products. In their Perspective, Bellows and Tyers discuss an elegant forward chemical genetic screen that identifies small-molecule inhibitors called ubistatins that disrupt the cell's protein degradation machinery (Verma et al.). This work is an excellent example of the systematic identification of small-molecule inhibitors of complex biological processes and the characterization of their molecular targets.
The authors are at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada. E-mail: tyers{at}mshri.on.ca
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Rati Verma, Noel R. Peters, Mariapina D'Onofrio, Gregory P. Tochtrop, Kathleen M. Sakamoto, Ranjani Varadan, Mingsheng Zhang, Philip Coffino, David Fushman, Raymond J. Deshaies, and Randall W. King (1 October 2004) Science306 (5693), 117.
[DOI: 10.1126/science.1100946] |Abstract »|Full Text »|PDF »|Supporting Online Material »